-
In 2023, the pharmaceutical industry policy eased and stabilized, and it is recommended to focus on these three areas
Time of Update: 2023-02-03
Innovative drugs: In recent years, the development of the innovative drug industry has continued, the supply of high-quality has continued to increase, and the company's domestic business + overseas business has continuously achieved breakthroughs.
-
The market of more than 10 billion anti-AIDS drugs has attracted pharmaceutical companies to layout, and another domestic class 1 new drug is launched in the new year!
Time of Update: 2023-02-03
Another domestic anti-AIDS class 1 new drug was launched On January 5, Addi Pharmaceutical announced that the company's research and development of enomiti tablets (trade name: Fubond) was approved for marketing.
-
The State Food and Drug Administration approved the application for supplementation of production and capacity expansion of 5 symptomatic treatment drugs for new coronavirus infection, including ibuprofen tablets
Time of Update: 2023-02-03
Annex: List of varieties serial number Name of the drug Marketing Authorization Holder 1 Ibuprofen tablets Shandong Xinhua Pharmaceutical Co.
Annex: List of varieties serial number Name of the drug Marketing Authorization Holder 1 Ibuprofen tablets Shandong Xinhua Pharmaceutical Co.
-
Improving innovation capabilities has become a general trend in the industry, and pharmaceutical equipment companies will continue to increase investment in research and development in the future
Time of Update: 2023-02-03
In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network) It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development of the industry.
-
In 2022, the sales of ibuprofen are expected to exceed 1.4 billion yuan, and China Resources Sanjiu and Renfu will enter the market to grab food
Time of Update: 2023-02-03
According to data, since the beginning of this year, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing.
According to data, since the beginning of this year, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing.
-
Many places in China have issued implementation plans for the new crown infection "Class B tube"
Time of Update: 2023-02-03
Recently, many provinces in China have successively introduced specific implementation plans for the "Class B and B tube" of new crown infection, increased investment in the construction of medical resources, increased fever clinics, clarified the reimbursement policy of medical insurance for new crown infection, and ensured the needs of the people for medical treatment.
-
On-site negotiations on the national medical insurance drug catalogue in 2022 begin! What are the concerns?
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On January 5, the on-site negotiation of the 2022 National Medical Insurance Drug Catalogue officially began, which attracted the attention of the pharmaceutical industry and the general patient group.
-
Comparable to the world's most expensive drug of $3.5 million, Pfizer hemophilia B gene therapy Phase 3 clinical data is positive
Time of Update: 2023-02-03
Recently, Pfizer announced that its gene therapy for severe hemophilia type B Fidanacogene Elaparvovec has achieved excellent results in a Phase 3 clinical trial, reaching the primary clinical endpoint, and the number of annual bleeding times in patients receiving gene therapy was 1.
-
The State Food and Drug Administration approved the marketing of the new Chinese medicine drug Qi Jiao Jingjing Granules
Time of Update: 2023-02-03
The drug has carried out multi-center, randomized, double-blind, marketed parallel controlled clinical trials of traditional Chinese medicines.
The drug has carried out multi-center, randomized, double-blind, marketed parallel controlled clinical trials of traditional Chinese medicines.
-
Bei Shen Pharmaceutical: a listed enterprise on the New Third Board, focusing on the inheritance and innovation of traditional Chinese medicine, and being an expert in respiratory medicine
Time of Update: 2023-02-03
With the brand concept of "focusing on the inheritance and innovation of traditional Chinese medicine, and carrying forward the characteristics of traditional Chinese medicine", Bei Shen Pharmaceutical has experienced 22 years of development, and now has 14 drug approval numbers, 7 dosage form production lines, and an annual total production value of 500 million.
-
In 2023, there will be active mergers and acquisitions in the pharmaceutical circle, involving Aier Ophthalmology, China Resources Pharmaceutical, Dajia Wellcom, etc
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];M&A is a common action of pharmaceutical companies, and due to the impact of the epidemic in 2022, the market has cooled down, and the overall M&A activity of the pharmaceutical industry has declined.
-
CStone Pharmaceuticals' registrational clinical study for the first-line treatment of esophageal squamous cell carcinoma has reached the primary endpoint and intends to submit a marketing application for ® a new indication
Time of Update: 2023-02-03
On January 3, 2023, CStone Pharmaceuticals (02616. HK) reported that its potentially best-in-class PD-L1 antibody Zogeminec (sugemelimab ® injection) first-line clinical study for esophageal squamous
-
Three departments: It is strictly forbidden for old-age institutions to carry out medical services in violation of laws and regulations
Time of Update: 2023-02-03
According to the notice, the National Health Commission, the Ministry of Civil Affairs, and the State Administration of Traditional Chinese Medicine have guided all localities to carry out the investigation and rectification of illegal acts of unqualified medical institutions set up in elderly care institutions and relevant personnel without medical qualifications providing diagnosis and treatment services without authorization, and found that some elderly care institutions have relevant violations of laws and regulations.
-
How to use Chinese medicine decoction well for urban and rural grassroots epidemic prevention and control? How to effectively choose Chinese medicine formulas after infection? ——Authoritative experts interpret hot issues in epidemic prevention
Time of Update: 2023-02-03
The use of medicinal decoctions in urban and rural areas to carry out the treatment of new coronavirus infection is an important measure for us to adopt the "Chinese method" to solve China's anti-epidemic problem.
-
The net outflow of funds of 5 pharmaceutical and biological stocks exceeded 100 million yuan, involving Yiling Pharmaceutical and Zhongsheng Pharmaceutical
Time of Update: 2023-02-03
According to the statistics of capital flow data, among the stocks with a net outflow of funds from the pharmaceutical and biological industry on December 29, there were 5 stocks with a net outflow o
-
The State Food and Drug Administration approved the import registration of Monoravir capsules, Merck's new coronavirus treatment drug
Time of Update: 2023-02-03
(Zhongxin Finance) According to the official website of the State Food and Drug Administration, on December 29, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special approval procedures for drugs, and conditionally approved the import registration of Merck's new coronavirus treatment drug monogravir capsules (trade name: Lizhuorui/LAGEVRIO).
-
Domestic pharmaceutical companies stormed the 100 billion anti-tumor drug market, and there is good news!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Recently, CT Tianqing Pharmaceutical's self-developed Class 1 new drug TQB2102 for injection has obtained the implied license of clinical trials and is intended to be used for the treatment of advanced malignant tumors.
-
Accelerate the layout of diabetes, and strive for the research and development of new anti-aging drugs... At the beginning of the new year of 2023, pharmaceutical companies are busy with financing
Time of Update: 2023-02-03
Sihuan Pharmaceutical recently announced that Huisheng Biotechnology, a non-wholly-owned subsidiary of the Group, has successfully completed the Series A+ financing conducted by Jilin Baixing Bai Rong Investment Center (Limited Partnership), Jilin Equity Fund Investment Co.
-
In 2023, the price of Yanhusuo is expected to fall, and Longshen Rongfa's profit will grow!
Time of Update: 2023-02-03
According to the company's 2022 half-year report data, Yuanhu painkiller pills occupy a high share in Yuanhu painkiller series products due to their exclusive dosage form and unique curative effect, and currently account for 70% of the company's operating income.
-
Eli Lilly, Amgen, Pfizer and many pharmaceutical giants have sprinted to the "weight loss" market
Time of Update: 2023-02-03
It is reported that according to the results of the phase 3 clinical trial SURPASS-2 published by Lilly, compared with Novo Nordisk 1 mg injectable semeglutide, three doses of Tirzepatide can significantly reduce glycated hemoglobin and body weight from baseline in adult patients with type 2 diabetes.
